peran+perawat+dalam+pencegahan+gagal+ventilasi+pada+pasien+covid+19

Medicus Pharma Ltd. (NASDAQ: MDCX) Positioned for Growth in a $5 Trillion Biotech Market

Medicus Pharma Ltd (MDCX)

The global population is aging rapidly, with the number of people aged 65 and older expected to double by 2050. This demographic shift is driving a surge in chronic diseases such as cancer, autoimmune disorders, and cardiovascular conditions. At the same time, breakthroughs in biomedical research are enabling the development of targeted, more effective therapies, transforming treatment approaches in both human and veterinary medicine. These twin forces, rising demand fueled by aging and disease prevalence along with technological innovation, are propelling unprecedented growth across biopharma markets. The global biotechnology sector is projected to expand from $1.74 trillion in 2025 to over $5 trillion by 2034, representing a compound annual growth rate (CAGR) of 12.5 percent. Specialty pharmaceuticals, including biologics and novel drug delivery systems, are expected to grow even faster, with forecasts predicting a 26.5 percent CAGR over the same period. Oncology remains a key driver, with spending on cancer medicines forecasted to nearly double from $252 billion in 2024 to $441 billion by 2029. Meanwhile, veterinary oncology is emerging as a high-potential frontier, with the U.S. market alone projected to reach $1.48 billion by 2030, driven by rising pet ownership and demand for advanced care. The urology therapeutics segment also shows steady growth potential, expected to rise from $10.5 billion in 2024 to $15.8 billion by 2033. Amid this expansive and interconnected landscape, Medicus Pharma Ltd. (NASDAQ: MDCX) is methodically positioning itself to capitalize on these powerful market tailwinds. Through a diversified portfolio of innovative drug delivery platforms and targeted therapies, Medicus addresses some of the most pressing health challenges across human and veterinary medicine. Medicus Pharma: Methodically Building a High-Leverage Growth Story Though still flying under many investors’ radars, Medicus Pharma is rapidly assembling the elements of a high-leverage growth story. On June 2, the company completed a $7 million public offering, selling 2,260,000 units at $3.10 each. Each unit includes one common share plus one warrant exercisable at the same price over five years. The capital will primarily fund a Phase 2 proof-of-concept trial in basal cell carcinoma (BCC) using Medicus’s flagship doxorubicin-loaded dissolvable microneedle patch (D-MNA). Additional funds may support broader development in non-melanoma skin cancers or other pipeline programs. Strategic Veterinary Expansion: FDA Submission for Equine Squamous Cell Carcinoma This timely financing was quickly followed by a major regulatory milestone. On June 9, Medicus announced submission of a formal product development plan to the U.S. FDA for a veterinary application of D-MNA targeting equine squamous cell carcinoma (SCC). The program is advancing under an Investigational New Animal Drug (INAD) file, aiming for conditional approval. It leverages the same microneedle patch technology used in human dermatologic trials, demonstrating a strategic effort to repurpose clinical data and technology across human and veterinary markets. Tapping an Untapped Veterinary Oncology Opportunity The equine indication represents a significant market opportunity. As CEO Dr. Raza Bokhari highlighted, “In veterinary medicine, where only a handful of oncology drugs are approved, developing a non-invasive treatment for equine SCC targets a largely unmet need, a potential $250 million market.” The planned study will enroll 50 horses across five U.S. sites in a placebo-controlled design, comparing two D-MNA doses against placebo, with tumor response assessed at day 90. Medicus has secured FDA Minor Use in Major Species (MUMS) Designation, which grants seven years of market exclusivity upon approval, a valuable commercial advantage in a segment with limited competition. D-MNA Platform: Promising Safety and Efficacy Data The D-MNA patch, originally developed for human skin cancers, is supported by encouraging early data. A Phase 1 trial in Australia (SKNJCT-001) involving 13 patients with nodular BCC showed the treatment was well tolerated with no dose-limiting toxicities. Remarkably, 46 percent of lesions achieved complete histological clearance after a single application, an impressive result given the minimally invasive delivery. This platform delivers doxorubicin directly into the dermis through a biodegradable microneedle array, minimizing systemic exposure while concentrating the drug’s effect at the tumor site. Expanding Clinical Trials Across Continents Building on this foundation, Medicus is running two Phase 2 trials. In the U.S., the SKNJCT-003 study recently expanded enrollment from 60 to 90 patients following a positive interim analysis that showed over 60 percent clinical clearance. This multicenter, placebo-controlled trial compares the patch to the standard of care, with European sites now joining due to growing investigator interest. Concurrently, the SKNJCT-004 trial in the United Arab Emirates involves 36 patients across four hospitals, including Cleveland Clinic Abu Dhabi, targeting both histological and clinical clearance endpoints. Strategic Acquisition: Entering Late-Stage Urology Complementing its internal pipeline, Medicus is also positioning itself as a consolidator of high-value assets. In April, the company signed a binding letter of intent to acquire UK-based Antev Ltd., whose lead candidate, Teverelix, is a GnRH antagonist in late-stage development for two urology indications: acute urinary retention (AUR) due to benign prostatic hyperplasia and hormone-sensitive prostate cancer in patients at elevated cardiovascular risk. These combined markets represent a $6 billion annual opportunity, and Teverelix has completed multiple clinical trials in Europe. Under the deal, Antev shareholders would receive approximately 19 percent of Medicus’s post-merger equity, plus up to $65 million in milestone payments tied to regulatory and commercial successes. A Platform With Multiple Growth Levers Together, Medicus offers optionality and platform leverage across human oncology, veterinary medicine, and dermatology, all fields marked by limited innovation and strong pricing power. Its lead asset is already in Phase 2 with international trial sites and active FDA engagement. The veterinary program offers a faster commercialization path with fewer regulatory barriers, while the Antev acquisition could propel Medicus into late-stage, multi-billion-dollar indications. Why Investors Should Watch MDCX Medicus Pharma (NASDAQ: MDCX) paints the picture of a small-cap biotech transitioning from concept to execution. The recent capital raise was non-dilutive and immediately followed by a key regulatory filing. Clinical trials across humans and animals are expanding, and a transformative acquisition is imminent. With a methodical approach tying together clinical progress, intellectual property, and market strategy, Medicus is quietly building momentum, making MDCX a stock to watch closely in the second half of 2025. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by MDCX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

June 10, 2025 10:20 AM Eastern Daylight Time

Vocatus is Named a Finalist in the WealthManagement.com 2025 Industry Awards for Best Client PR Campaign

Vocatus

Vocatus, a leading communications and marketing firm serving the financial services industry, announced that it has been named a finalist in the Wealth Management 2025 Industry Award (the “Wealthies”) for Best Client PR Campaign. For the second year in a row, Vocatus has received the recognition, which centers on its work on behalf of Callan Family Office, a registered investment advisor serving ultra-high-net-worth families, family offices, foundations and endowments. In addition to its own accolade, Vocatus’ clients are finalists in 19 categories at the prestigious Wealthies in 2025. “We are honored and humbled by this recognition, but even more so, we feel immense gratitude to our clients who have placed their trust in us and given us the opportunity to share in their success,” said Ray Hennessey, Chief Executive Officer of Vocatus. “I want to thank my team and our industry peers for this honor. As we approach our three-year anniversary, I could not be prouder of what we’ve built and the opportunities yet to come.” Founded in 2022, Vocatus serves dozens of clients, from startups to some of the most established names in the financial services industry. Earlier this, Vocatus was awarded the Best Marketing or PR Campaign at the Family Wealth Awards. Last year, it was named a finalist in several well-known wealth management awards, including the WealthManagement.com Industry Awards and ThinkAdvisor Luminaries. Now in its 11th year, the Wealth Management Industry Awards is the only awards program of its kind to honor outstanding achievements by companies, organizations and individuals that support ﬁnancial advisor success. A panel of judges made up of top names in the industry, led by WealthManagement.com director of editorial strategy and operations David Armstrong, chose the ﬁnalists and will determine the winners. Each year, the Wealth Management Industry Awards recognize the ﬁrms and individuals who are making a real diﬀerence to the daily activities of ﬁnancial advisors. Winners will be announced at a gala and awards ceremony in New York City on September 4th. “The Industry Awards are a beacon, illuminating the trailblazers and innovators who are shaping the future of the ﬁnancial services industry,” said David Armstrong, director of editorial strategy and operations. “They serve as a leading indicator of future activity, and as a barometer for the dynamic ecosystem of companies and organizations that empower, support and enable advisor success who are driving the industry forward.” About Vocatus Vocatus is a leading communications, marketing and public relations firm, serving the financial services industry. With specialists across media and journalism, Vocatus provides high-level support to individuals and businesses, including wealth management firms, asset managers, fintech companies and business service providers. Contact Details Christina Diabo +1 201-400-7239 cdiabo@vocatusllc.com

June 05, 2025 09:10 AM Eastern Daylight Time

Shumate Engineering Presents Breakthrough Hybrid Dry Adiabatic Cooling Design, Passes Key Benchmark

The Hoyt Organization

In a major breakthrough for the data center industry, Shumate Engineering, a leading full-service MEP engineering firm specializing in mission-critical data center environments, has launched its new cooling design, which is proven to significantly reduce power and water consumption. Hybrid-Dry/Adiabatic-Cooling (HDAC), a patent-pending design, was presented last month at AFCOM’s Data Center World conference in Washington, D.C., to hundreds of industry insiders who agreed with the system. HDAC utilizes both wet and dry cooling techniques within a closed loop, has the potential to disrupt the sector – just as its grappling with the proliferation of artificial intelligence. “With the need for massive computing power taking hold around the world, the data center industry is booming right now; however, the power and water needed to cool the racks and keep them functioning has limited its progress,” said Daren Shumate, PE, founder and managing principal of Tysons, Va.-based Shumate Engineering. “Major data center projects backed by the biggest names in tech have resorted to drastic measures to meet this demand, including the construction of high-density data centers that span city blocks and recommissioning nuclear power plants, but our cooling design manages to use half of the power and less than 10 percent of the water compared to traditional data centers – offering a massive savings of natural resources and billions of dollars in costs.” This hybrid-dry adiabatic (HDAC) design was presented by Shumate and R. Stephen Spinazzola, PE, director of mission critical services at Shumate Engineering at the AFCOM conference. They explained how to get power usage effectiveness (PUE) for a hyperscale data center in the mid-Atlantic region – typically higher than 1.2 – down to a range between 1.1 to 1.06 PUE, depending on the ratio of traditional air cooled versus direct liquid cooled equipment. They followed up the presentation with a successful test at Baltimore Aircoil Company's testing facility where the system met all specific design requirements, including: Maintaining 68 deg F fluid supply temp up to 60 deg F ambient dry bulb Maintaining 90 deg F fluid supply temp up to 82 deg F ambient dry bulb Maintaining 90 deg F fluid supply temp up to 81 deg F ambient wet bulb “We are incredibly pleased with the performance of our HDAC design,” said Spinazzola, the creator of the design who already has six patents in his name. “This test verifies our claim that this system uses approximately the same water an air-cooled chiller system uses when combining on site and electrical power plant water use.” The timing couldn’t be more relevant. As global demand for high-performance data centers surges — driven largely by the exponential growth of artificial intelligence, machine learning, and cloud computing — cooling infrastructure has become a critical bottleneck. Shumate Engineering's groundbreaking solution addresses both the energy and environmental challenges associated with traditional evaporative and mechanical cooling methods. “Our new hybrid system is a game-changer,” Shumate said. “By dramatically reducing both energy and water consumption, we're enabling data center operators to scale up AI and high-density workloads sustainably and cost-effectively. It’s an engineering solution that meets the moment.” Unlike conventional systems that rely heavily on water-based evaporative cooling, Shumate Engineering’s HDAC design combines advanced dry cooling principles with prescribed adiabatic enhancements, optimizing thermal performance without compromising environmental responsibility. The result is a scalable, modular system that not only meets the intense thermal demands of AI-driven computing but also reduces operational costs and environmental footprint — a critical consideration as data centers face growing scrutiny over resource usage. “Considering that a typical ChatGPT query used 10 times more power than the average Google search, the future of computing demands a future-ready infrastructure,” Spinazzola said. “Our HDAC system keeps pace with technological advancements while meeting aggressive sustainability goals – cutting power usage in half and using just a sip of water." About Shumate Engineering Shumate Engineering is a full-service MEP engineering firm specializing in mission critical, data center environments. Its ever-growing roster of engineers have collaborated on many projects — from the namesakes of northern Virginia’s “Data Center Alley” and the rapidly growing DMV housing market to new prospects in Richmond and beyond. The team’s game-changing Hybrid Adiabatic Fluid Cooler - which uses half as much power and 90 percent less water than traditional cooling systems for AI data centers - is set to be approved by the U.S. Patent and Trademark Office this summer. Learn more at shumateengineering.com. Daren Shumate, Founder and Managing Principal of Shumate Engineering, boasts many accomplishments in data center design including is an engineering icon the Smithsonian Institution’s main data center in Herndon, eBay’s chief 26-megawatt Tier E structure in Utah, the NSA’s High Performance Computing Center in Ft. Meade, and the Fannie Mae-owned data center in Urbana that was the first of its kind to attain LEED. He is a licensed electrical engineer in more than 20 states and lives in the Washington, D.C. area. Steve Spinazzola, Director of Mission Critical Services for Shumate Engineering, offers more than 42 years of experience in both mechanical design and project management on corporate, mission-critical, educational, health and science, retail, and institutional projects. His game-changing Hybrid Adiabatic Fluid Cooler - which uses half as much power and 90 percent less water than traditional adiabatic cooling - is set to be approved by the U.S. Patent and Trademark Office this summer. ### Contact Details Shumate Engineering Andrew King +1 914-513-6895 aking@hoytorg.com Company Website https://shumateengineering.com

June 03, 2025 04:01 PM Eastern Daylight Time

The NAVEX 2025 Regional Whistleblowing Benchmark Report Highlights the Rise in Anonymous Reports

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, announces the findings of its 2025 Regional Whistleblowing & Incident Management Benchmark Report. It features an in-depth analysis of 2.15 million reports (the highest level ever) from NAVEX customers that received 10 or more internal reports in 2024. The analysis and report cover over 4,000 organisations across Europe, Asia Pacific (APAC), North America and South America, representing nearly 70 million employees covered by their programs. Key findings include: Report Volume: Organisations headquartered in North America received more than twice the report volume of those in Europe and Asia Pacific. When comparing 2023 and 2024, Europe saw the largest increase (0.49 to 0.67 reports per 100 employees) to the highest reporting levels seen for this region. It is notable that all four geographies in the NAVEX analysis have seen a general increase in median reports per 100 employees over the last four years. Case Closure Time: While organisations in Europe and APAC received fewer reports, they are taking far longer to investigate and close them with the highest median case closure times (Europe at 69 days, APAC at 56 days). In comparison, North America was at 19 days. This data may be influenced by differences in the types of reports received in each region. However, in all regions, regardless of the time to close a case, the substantiation rate of cases consistently ranged from 45% to 48%. It is important to highlight that nearly half of all reports received globally are substantiated. Time to Report: Organisations based in Europe and APAC saw a higher time difference between incident and report date (the number of days between when the matter occurred or was witnessed and when the report is filed). In Europe, the median time difference between the incident and the report was 13 days, for APAC it was 12. The time difference in North America was 8 days. This is important because reporters who delay reporting may fear retaliation or not know where to make the report. In addition, Europe, APAC, and South America had the highest median rates of anonymous reports (65%, 67%, and 70% respectively), compared to just over half (52%) in North America. Higher levels of anonymous reporting can also be an indication of fear of retaliation making this a metric to watch. Retaliation Cases: With the EU Directive’s focus on whistleblower protection, it is important to note that by headquarters region, Europe-based organisations substantiate retaliation cases at 32%, nearly double the rate of North America which achieved a four-year high of retaliation substantiation of 17% in 2024; APAC had a substantiation rate for retaliation reports of 28% for 2024. Reporting Channels: The NAVEX report looked at reports received via a phone channel (hotline), web-based reporting, and “other” which can be walk-ins to compliance or human resources. In North America, by frequency, the hotline is used for 31% of reports – significantly above Europe (18%) and even more than APAC (11%). Reporting by Ownership Type: Finally, new this year, NAVEX analysed internal reporting data for different structures of company ownership – publicly traded companies, private organisations, government entities and education entities – to show how reporting metrics differ within these groups with notable findings. Privately owned companies are more likely to substantiate reports across the board, with Europe and APAC at 50%, North America at 49%, and South America at 67% substantiated. Conversely, public companies’ substantiation rate was below 50% for all regions – Europe at 45%, APAC at 47%, North America at 42%, and South America at 43%. “Creating trusted channels for internal reporting is one of the most effective ways to prevent small issues from becoming major liabilities,” said Carrie Penman, Chief Risk and Compliance Officer at NAVEX. “Organisations with robust internal and third-party reporting programs have real-time intelligence to understand emerging risk and cultural health within their workforce and supply chains.” For more exclusive insights, join the 2025 Regional Whistleblowing & Incident Management Benchmark Report webinar at 1pm BST on 5 June. Andy Noble, Head of Whistleblowing at NatWest Group, will be joined by NAVEX experts, Carrie Penman, Chief Risk and Compliance Officer, and Jan Stappers, Director of Regulatory Solutions, to host an informative discussion on the results of this year’s analysis. Trusted by over 13,000 organizations, including 70 percent of Fortune 100 and 500 companies, NAVEX is the global leader in risk and compliance solutions. Its NAVEX One platform strengthens risk and compliance programs, empowering organizations with unparalleled industry benchmark data and insights. NAVEX One provides a 360-degree view of enterprise, third party and ecosystem risk for enhanced regulatory compliance and proactive risk management. Based in Lake Oswego, OR, with a global presence, NAVEX continues to shape the future of governance, risk and compliance. Visit our blog or follow us on LinkedIn, Facebook, and YouTube. Contact Details NAVEX +1 617-388-5773 anita.lo@navex.com Company Website https://navex.com

June 03, 2025 07:13 AM Eastern Daylight Time

Inspira Technologies Receives $2 Price Target and Buy Rating: Everything You Need to Know

Global Markets News

Litchfield Hills Research has initiated coverage of Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN)* with a Buy rating and a $2 price target, representing potential upside of over 225% from current trading levels of around $0.61 per share. This bullish outlook comes as the medical technology company continues to critical care technology addressing what the analyst describes as "a medical need without good options." The analyst notes that mechanical ventilators are "WWII technology in desperate need of an upgrade" with reports showing that 30% to 50% of ICU patients don't survive. Unlike mechanical ventilation, Inspira's ART500 technology would enable patients to remain awake during treatment while stabilizing oxygen levels without intubation and coma. What distinguishes Inspira from typical early-stage medical device companies is its proven regulatory execution and early commercial success. The company's first generation technology, the INSPIRA ART100 system, received FDA clearance in May 2024 and is already deployed in leading U.S. hospitals. The excitement around this technology reached a new high in April 2025 when the first successful patient treatment was completed at Westchester Medical Center. The commercial momentum seems to be accelerating. Inspira announced it received payment in the "low hundreds of thousands of dollars" from its U.S. distributor for delivered systems, marking the company's first revenues. CEO Dagi Ben-Noon called this "a transformative milestone for Inspira as we establish our presence in the U.S. medical landscape." The company has now initiated global commercial rollout discussions and expects additional deliveries in the second half of 2025. Central to Inspira's technology platform is the AI-powered HYLA blood sensor, which recently achieved 96% accuracy in clinical studies at Sheba Medical Center, one of the world's top hospitals. The system provides continuous monitoring without requiring blood draws, targeting the blood gas analyzer market projected to reach $5.7 billion by 2030. The analyst identifies massive market opportunities, with the global mechanical ventilators market expected to reach $20.69 billion by 2034. Inspira's flagship INSPIRA ART500 system in development aims to disrupt this market by providing respiratory support through direct blood oxygenation rather than forcing air into damaged lungs. Inspira has established strong intellectual property protection with multiple U.S. patents and novel patent claims protecting its core technologies. The company is executing a strategic approach of securing FDA clearance for individual components before integrating them into comprehensive systems. When comparing Inspira to similar medical device companies, the analyst found the stock trades at significant discounts despite having FDA-cleared technology already treating patients. The $2 price target reflects confidence in the company's ability to capitalize on its early commercial success and expand into the massive mechanical ventilation market. The analyst concludes that Inspira may represents a unique opportunity, combining proven FDA-cleared technology with substantial market opportunity and attractive valuation metrics in the high-growth medical device sector. Recent News from Inspira: Inspira Technologies Initiates Global Commercial Rollout of FDA-Cleared ART100 System INSPIRA ART100 System Approved by Israel's Largest Healthcare Provider for Use in Organ Transplant Patients Inspira Achieves above 99% Gas Exchange Efficiency in VORTX™ Technology In-Vivo Animal Testing * Legal Disclaimer & Disclosure: Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by the Wall Street Wire platform & media network. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This article contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire, which includes a monthly fee of five thousand US dollars paid in cash via bank transfer in return for promotional content and distribution services. The operators also receive additional fees for non promotional advisory and data services. Inspira Technologies did not necessarily review or approve this content prior to publication. Please review the full disclaimers and compensation disclosures here which include further details: redditwire.com/terms. We are not responsible for third party analyst price targets or market estimates are refer to them based on publicly availble reports. Additional or competing price target may exist and readers are advised to refer to the full report and its respective disclaimers and disclosures. Contact Details Wall Street Wire Editorial Desk media.globalmarkets@gmail.com

June 02, 2025 09:19 AM Eastern Daylight Time

THE MAERCKS INSTITUTE: WHERE INNOVATION, ELEGANCE, AND ZERO-PAIN AESTHETIC SURGERY CONVERGE

The Maercks Institute

In a world where aesthetic procedures are increasingly sought after, patients are becoming more discerning—demanding not only exceptional results, but also safety, minimal downtime, and a truly elevated surgical experience. For over 15 years, The Maercks Institute in Miami has quietly set the gold standard for precisely this level of care. At its helm is Dr. Rian Maercks, a board-certified plastic surgeon with elite training from Duke University Medical Center and an international reputation for aesthetic innovation, safety, and elegance in results. Dr. Maercks’ expertise is not confined to the American academic tradition alone. His advanced surgical training and aesthetic experience span the globe—gaining exposure to the most prestigious and forward-thinking techniques across Europe, Central America, and South America. This global perspective informs his deeply nuanced understanding of beauty and anatomy across diverse cultures and aesthetic ideals, shaping the distinctive and tailored approach for which The Maercks Institute is known. Sophisticated patients from around the world turn to Dr. Maercks not only for his artistry, but for a singular promise: surgical excellence without pain, without opioids, and without the extended recoveries typically associated with aesthetic enhancement. EXAREL AND THE MAERCKS METHOD™: A BREAKTHROUGH IN PAIN-FREE, NO-DOWNTIME SURGERY The Maercks Institute offers something rarely found in aesthetic surgery today—a comprehensive array of aesthetic and corrective procedures performed with zero pain and often no need for post-operative narcotics. At the core of this revolutionary approach is Dr. Maercks’ proprietary integration of Exparel, an advanced, FDA-approved, liposomal formulation of bupivacaine that slowly releases local anesthetic over 72 hours. By combining this with his proprietary tumescent Exparel technique—which includes careful dilution, epinephrine augmentation, and a deep understanding of the gate control theory of pain—Dr. Maercks delivers procedures from deep-plane facelifts to breast augmentations with unprecedented patient comfort. Patients receive a full regional nerve block using Exparel before any incision is made. Even when general anesthesia is employed, the body is completely anesthetized locally, preventing the brain from registering pain signals both during and after surgery. The result? Patients consistently awaken feeling as though they haven't had surgery at all. They walk out of the Institute unaided, smiling, and often singing—as documented in hundreds of post-op videos at @themaercksinstitute. Remarkably, patients undergoing facelifts, body contouring, and complex revision surgeries at The Maercks Institute routinely report needing no opioids such as Percocet, no extended recovery period, and no memory of discomfort—just beautiful, natural-looking results. NATURAL REJUVENATION WITHOUT THE TELL-TALE SIGNS: THE MAERCKS LIFT As recently highlighted by the American Society of Plastic Surgeons in their article "The Mid-Facelift is Taking Facial Aesthetics by Storm", the modern patient is seeking discreet rejuvenation with minimal interruption to their lives. In response, Dr. Maercks has pioneered the MAERCKS Lift, a deep-plane midface and lower face rejuvenation technique that restores natural contours without distortion or downtime. Unlike superficial “skin pulling” methods or trendy, temporary fixes, the MAERCKS Lift works by re-supporting the deeper tissues of the face and midface along natural vectors of aging. This allows for a profoundly youthful result without the overly tight or artificial appearance seen in many conventional facelifts. Because of his innovative approach, Dr. Maercks is widely considered the go-to expert for patients desiring subtle yet significant rejuvenation. Importantly, Dr. Maercks also emphasizes holistic harmony: “A rejuvenated face must be seen in context,” he explains. “Neglecting the neck or jawline creates disharmony that patients intuitively recognize. That's why I often integrate micro-lifting or lateral platysmaplasty techniques—even in minimally invasive cases—without adding downtime or discomfort.” THE MAERCKS INSTITUTE EXPERIENCE: DISCRETION, EXCELLENCE, AND GLOBAL RECOGNITION Discerning patients seeking surgical or non-surgical facial rejuvenation, breast and body enhancement, or revision procedures find in The Maercks Institute a sanctuary of both advanced science and aesthetic artistry. With a concierge-style approach to care, elite surgical techniques, and an unwavering focus on safety and sophistication, the Institute attracts a global clientele of business leaders, public figures, and patients who value discretion and excellence. Dr. Maercks’ broad and prestigious international training through Europe, Central America, and South America allows him to draw from a uniquely diverse foundation of aesthetic understanding. This international influence has been a key driver in developing his signature techniques—each refined to prioritize safety, individuality, and natural elegance. With over 15 years in private practice, hundreds of zero-downtime success stories, and an ongoing commitment to pushing the field forward, he has earned his reputation as a trusted authority in the evolving world of plastic surgery. SCHEDULE A PRIVATE CONSULTATION For patients who value both innovation and elegance—and who are unwilling to compromise on safety or recovery—The Maercks Institute offers a uniquely refined path to self-enhancement. Discover what it means to undergo a procedure without pain, without opioids, and without sacrifice. To schedule a private consultation or learn more about our services, visit www.themaercksinstitute.com or contact the Institute directly at (305) 328-8256. Contact Details Courtney Daniels Consulting Courtney Daniels courtney@cocodaniels.com Company Website https://www.themaercksinstitute.com/

May 27, 2025 10:00 AM Eastern Daylight Time

HNO International Launches HyGrid™: Intelligent Hydrogen Microgrid System to Power the Future of Distributed Hydrogen Infrastructure

HNO International

HNO International, Inc. (OTC: HNOI), a leading innovator in hydrogen-based clean energy solutions, proudly announces the launch of HyGrid™, its next-generation, intelligent hydrogen microgrid system. Purpose-built to deliver clean, uninterrupted, off-grid electricity, HyGrid will also serve as the foundational platform for a globally distributed hydrogen infrastructure — enabling hydrogen production, storage, and refueling virtually anywhere. HyGrid combines solar energy, hydrogen storage, advanced electrolyzers, AI-driven controls, and fuel cell backup into one seamless, modular system. With capacities ranging from 10kW micro-units to multi-megawatt deployments, HyGrid™ provides 24/7, zero-emission power even in the most remote or energy-challenged regions. “HyGrid isn’t just a power system — it’s the cornerstone of a decentralized hydrogen future,” said Don Owens, Chairman and CEO of HNO International. “By embedding hydrogen generation and storage into the energy fabric of communities, industries, and nations, HyGrid enables a cleaner, more resilient energy ecosystem — site by site, region by region.” Key Features of HyGrid™ Anywhere & Everywhere Power – Delivers reliable energy independent of the grid, with solar-hydrogen hybrid architecture for 24/7 operation. Foundation for Distributed Hydrogen Infrastructure – Each HyGrid deployment becomes a local node for hydrogen generation, storage, and future refueling. AI-Driven Energy Management System (EMS) – Enables predictive maintenance, load balancing, real-time analytics, and optimized energy flow. Fuel Cell Backup & Optional Battery Storage – Provides uninterrupted power during demand surges or low sunlight periods. Customizable & Scalable – Supports applications from rural electrification and critical infrastructure to military bases and smart cities. Building the Hydrogen Economy from the Ground Up With HyGrid, HNOI envisions a new hydrogen economy built from the ground up — distributed, modular, and resilient. Each system serves as a self-contained hydrogen production and power unit, reducing dependency on centralized grids and fossil fuels. As more HyGrid units are deployed across regions, they collectively form a networked infrastructure capable of fueling transport fleets, industrial facilities, emergency services, and even hydrogen-based commerce. “HyGrid enables a future where hydrogen isn’t just produced at a few massive plants — it’s generated locally, cleanly, and economically, everywhere people need power,” Owens added. “This is the blueprint for energy independence.” HNO International (OTC: HNOI) develops scalable, intelligent hydrogen energy systems that power the future of clean, distributed infrastructure. With over 15 years of hydrogen R&D and 19 U.S. patents, HNOI delivers pioneering technologies including the Scalable Hydrogen Energy Platform (SHEP™), Compact Hydrogen Refueling Station (CHRS™), and the newly launched HyGrid™ system — all designed to accelerate the global shift to sustainable energy. This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K, our quarterly reports on Form 10-Q and other periodic reports filed from time to time with the Securities and Exchange Commission. For more information, please visit www.sec.gov. Contact Details Donald Owens +1 951-305-8872 dowens@hnointl.com Company Website https://hnointl.com/

May 21, 2025 08:00 AM Eastern Daylight Time

Tether on TRON Surpasses $75 Billion, Tops All Stablecoin Activities

TRON DAO

May 19, 2025 - Geneva, Switzerland - TRON DAO announced today that the total circulating supply of Tether (USDT) on the TRON blockchain has surpassed $75 billion, once again making TRON the leading network for USDT. As the most widely adopted stablecoin, Tether represents more than 63 percent of the global market share with over $150 billion in circulation. Over 50 percent of that supply is issued on TRON - the #1 network among all blockchain networks for USDT total issuance, total transaction volume, and daily active users. As of May 2025, TRON supports over 8.3 million daily transactions and has surpassed 306 million user accounts on the blockchain. The network processes an average of $20 billion in daily USDT transfers. TRON leads in total transfer volume, facilitating nearly 29 percent of all stablecoin transaction value globally, reflecting its growing role as the preferred settlement network. TRON also leads in active user engagement with over 1 million unique accounts transacting USDT daily, accounting for 28 percent of all active stablecoin wallet addresses across blockchains. Accounting for over 55% of all USDT transaction volume, USDT on TRON continues to experience sustained and accelerating growth, reflecting rising global demand for efficient, low-cost, and reliable digital dollar infrastructure. This milestone reflects TRON's role in enabling a wide range of real-world financial use cases, from high-volume retail payments to institutional-scale transactions. As global demand for stablecoins grows, particularly for cross border settlement and financial access, TRON has become a trusted and widely adopted blockchain network, offering the scale, speed, and efficiency required to support stablecoin transactions at a global level. “TRON’s growth is driven by a strong alignment with the core values of the crypto industry, including financial freedom and individual empowerment,” said Justin Sun, founder of TRON. “USDT on TRON has become the preferred choice for millions of users around the world because it is fast, stable, and accessible. The focus remains on delivering real world utility and building strong network effects that make TRON the leading platform for stablecoin transactions.” The circulating supply of USDT grew by approximately 7 billion dollars in the first quarter of 2025, alongside an increase of 46 million user wallets. This growth reflects rising trust in Tether’s transparency and its role as a reliable representation of the U.S. dollar. It also reinforces USDT as a stable, efficient, and accessible on-ramp to the global economy. As TRON continues as the leading network for USDT, its ecosystem is evolving to meet the growing institutional demand for secure, scalable, and secure digital asset infrastructure. In April 2025, World Liberty Financial selected TRON to integrate their stablecoin, USD1. TRON and Tether have also deepened their commitment to financial integrity through the T3 Financial Crime Unit (T3 FCU), a joint initiative with TRM Labs. Since its launch, the T3 FCU has collaborated with global law enforcement agencies to freeze over $160 million in illicit funds. About TRON DAO TRON DAO is a community-governed DAO dedicated to accelerating the decentralization of the internet via blockchain technology and dApps. Founded in September 2017 by H.E. Justin Sun, the TRON blockchain has experienced significant growth since its MainNet launch in May 2018. TRON hosts the largest circulating supply of USD Tether (USDT) stablecoin, exceeding $75 billion. As of May 2025, the TRON blockchain has recorded over 306 million in total user accounts, more than 10 billion in total transactions, and over $23 billion in total value locked (TVL), based on TRONSCAN. TRONNetwork | TRONDAO | X | YouTube | Telegram | Discord | Reddit | GitHub | Medium | Forum Media Contact Yeweon Park press@tron.network Contact Details Yeweon Park press@tron.network Company Website https://trondao.org/

May 19, 2025 05:38 PM Eastern Daylight Time

Image

Giant Mining Advances Majuba Hill with Completion of 5,484.5 Ft Spring 2025 Drill Program

Giant Mining Corp.

VANCOUVER, BC — May 19, 2025 — Giant Mining Corp. (CSE: BFG | OTC: BFGFF | FWB: YW5) (CSE:BFG.WT.A) (“Giant Mining” or the “Company”) is pleased to announce the successful completion of Phase 1 of its 2025 spring diamond core drilling program ( "Core Program" ) at the Majuba Hill Porphyry Copper-Silver-Gold Project ( "Majuba Hill" ) in Pershing County, Nevada. Equipment demobilization has concluded, and the Company is now preparing for comprehensive analysis of drill core samples, aiming to define geological controls and further delineate mineralization. A total of five drill holes, MHB-32 through MHB-36, were completed for a combined 5,484.5 feet (1,671.68 meters) of core drilling. This brings the cumulative total of drilling at Majuba Hill to 89,395 feet (27,247.5 meters), which will significantly enhance the Company’s geological model and support future deposit development. Table 1: Majuba Hill 2025 Drill Program Collar Details The primary objective of the Core Program was to step out from and expand the known zones of copper mineralization and advance the Majuba Hill Project toward completing a Mineral Resource Estimate ( “MRE” ). All drill core was transported to Giant Mining’s secure core facility in Elko, Nevada, where it was logged, sawn, and sampled by Company personnel. The samples were submitted to ALS Global Services ( “ALS Labs” ) for geochemical analysis, with sample preparation completed at their Elko facility and final assaying conducted at their laboratory in Vancouver, British Columbia. David Greenway, CEO of Giant Mining, commented: “The 2025 drill season has been our most exciting and technically ambitious to date. We began the program with strong visual mineralization that exceeded expectations, prompting us to add a fifth drill hole—MHB-36—guided by AI-assisted geophysical modeling. This AI-predicted target intersected promising mineralization, suggesting a potential new discovery and was a meaningful step-out from previously defined zones. Notably, MHB-33 was drilled to a depth of 1,963 feet and encountered significant native copper, expanding our understanding of the scale and potential of the Majuba Hill Copper-Silver-Gold system. We now eagerly await assay results from ALS Labs as we work toward completing an NI 43-101 Mineral Resource Estimate to support future development plans.” Key highlights include: MHB-32 – Starting with a Bang Core Hole MHB-32 was completed to a total depth of 889.5 feet (271.1 meters). The hole intersected copper-bearing magmatic-hydrothermal breccias with secondary copper minerals, including azurite, malachite, and chalcocite. These transitioned into strongly oxidized copper sulfides, with primary, unoxidized chalcopyrite near the bottom of the hole. Click Image To View Full Size Figure 1: MHB-32 - Azurite, malachite, chalcocite in magmatic-hydrothermal breccia at 527 to 537 ft (160.-163. m). This early success confirmed the vertical continuity of the mineralized system and the presence of high-potential breccia-hosted copper zones. Click Image To View Full Size Figure 2: MHB-32 – Clast of intrusive with chalcopyrite in tourmaline/chalcopyrite matrix breccia at 810 ft (246.89 m). MHB 34 – Native Copper Encounter Core Hole MHB-34 was drilled to a total depth of 1,963 feet (598.3 meters). The hole encountered persistent native copper, cuprite, and chalcopyrite mineralization in its deeper sections, with native copper observed beyond 1,850 feet. Click Image To View Full Size Figure 1: MHB-34 at 1,499 ft (456.9 m) Native Cu on fracture HQ Core, 2.5-inch (63.5 mm) diam. These results indicate a robust porphyry system at depth and suggest proximity to a primary copper sulfide source. MHB 36 – An A.I. Driven Step Out Discovery and Potential Deposit Extension Click Image To View Full Size The fifth and final drill hole of the Core Program, MHB-36, was planned for a total depth (TD) of 1,000 feet (304.8 meters). This hole was designed by Exploration Technologies ( “ExploreTech” ) using its proprietary AI-assisted geophysical modeling system to test a high-potential resistivity anomaly delineated in the southern sector of the Majuba Hill project area. The AI-driven targeting approach aimed to identify geologically favorable zones with potential for new copper mineralization beyond the existing mineralization footprint. Figure 2: 3D Model of Majuba Hill, showing the five drill collars and summarized results for MHB-36. Right: Downhole plot of drilling results and ExploreTech prediction, showing predicted probability of sulfide mineralization and the true intersection (dashed grey). Due to the intersection of the sulfides predicted by modeling the hole was extended to 1100 feet (335.28 meters). MHB-36 intersected disseminated and vein-hosted chalcopyrite mineralization within intrusive and magmatic hydrothermal breccias, beginning at a downhole depth of 650 feet (198 meters). Mineralization was observed intermittently beyond 905 feet (274.32 meters), confirming the accuracy of the AI model and highlighting the potential for further extensions of copper-bearing zones in this underexplored area. Click Image To View Full Size Figure 3: MHB-36/935 feet (285 m). Disseminated chalcopyrite in Intrusive. Majuba Hill’s critically important characteristics are as follows: Quality Assurance/Quality Control (“QA/QC”) Measures, Chain of Custody The Company utilizes a QA/QC program using best industry practices at the Majuba Hill Project. The samples are placed in cloth sample bags and are transported from the Giant Mining secure warehouse to the ALS Labs Sample Prep Facility in Elko, Nevada. ALS Labs then securely transports the prepared pulps to their analytical lab in North Vancouver, B.C. Drill core samples are sawn in half lengthwise and one half is placed in labeled cloth sample bags. All samples are analyzed for copper, gold, silver, and 33 other elements. Gold is determined by ALS Labs method Au-AA23 which is a fire assay with an AAS finish on a 30-gram split. Copper, silver, and the remaining 31 elements are determined by ALS Labs method ME-ICP61 which is a four-acid digestion and ICP-AES assay. Approximately 5% of the submitted samples are drill duplicates and copper-gold-porphyry commercial standard reference material pulps. The remaining pulps will be retrieved from ALS Labs. Qualified Person The scientific and technical information contained in this news release has been reviewed and approved by E.L. “Buster” Hunsaker III, CPG 8137, a non-independent consulting geologist who is a “Qualified Person” as such term is defined under National Instrument 43-101 – Standards of Disclosure for Mineral Projects ( “NI 43- 101” ). About Giant Mining Corp. Giant Mining is focused on identifying, acquiring, and advancing late-stage copper and copper/silver/gold projects to meet the growing global demand for critical metals. This demand is driven by initiatives like the Green New Deal in the United States and similar climate-focused programs worldwide, which require substantial amounts of copper, silver, and gold for electric vehicles, renewable energy infrastructure, and the modernization of clean and affordable energy systems. The Company’s flagship asset is the Majuba Hill Copper, Silver, and Gold District, located 156 miles (251 km) from Reno, Nevada. Majuba Hill is situated in a mining-friendly jurisdiction with supportive regulations and has the potential to become one of the next major copper deposits, critical for meeting the increasing need for this red metal. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. On Behalf of the Board of Giant Mining Corp. “David Greenway” David C. Greenway President & CEO For further information, please contact: E: info@giantminingcorp.com P: 1 (236) 788-0643 VISIT OUR WEBSITE FOR MORE DETAILS www.giantminingcorp.com LIKE AND FOLLOW Instagram, Facebook, Twitter, LinkedIn DOWNLOAD INVESTOR INFORMATION Click Here Forward-Looking Statements This news release contains certain forward ‐ looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward ‐ looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward ‐ looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward ‐ looking statements, whether as a result of new information, future events or otherwise. ###

May 19, 2025 09:56 AM Eastern Daylight Time

Image

1 2 3 4 5 ... 513